U nhú và HPV trong nha khoa

An Etiological and Clinicopathological Monograph on Papillomatous Neoplasms

I. Defining the Papilloma: A Histopathological and Etiological Framework

A. Morphological and Histological Definition

In medical nomenclature, a papilloma is fundamentally defined as a circumscribed, benign (noncancerous) epithelial neoplasm.1 Its primary characteristic is an exophytic growth pattern, meaning it arises from an epithelial surface—such as the skin or the lining of an organ—and grows in an outward direction, projecting from the surrounding tissue.1 The histopathological architecture of a papilloma is its most defining feature. Microscopically, it is composed of villous or arborescent (tree-like) outgrowths.2 These are more commonly described as frond-like or finger-like projections.1 Each individual projection, or papilla, possesses a central fibrovascular core.1 This core, composed of connective tissue and blood vessels, provides essential structural support and a nutrient supply to the lesion.1 This supportive core is covered by a layer of proliferating, neoplastic epithelial cells, the nature of which reflects the tissue of origin.1 This covering may be stratified squamous epithelium (in the skin, oral mucosa, or cervix), urothelium (in the bladder), or ductal epithelium (in the breast).1 This underlying microscopic structure dictates the macroscopic, or clinical, appearance of the lesion. On cutaneous (skin) surfaces, this structure often results in rough, solid, and hyperkeratinized papules (warts).1 On mucosal surfaces (such as the mouth or genitals), the lesions are typically soft, pedunculated (supported by a stalk), or sessile (broad-based) masses.1 The appearance of these mucosal lesions is often dependent on their keratin content. Heavily keratinized lesions appear white and are frequently described as "cauliflower-like".1 Lesions with less keratinization are pink or red and may resemble a "raspberry".1

B. The Central Etiology: Human Papillomavirus (HPV)

While the term "papilloma" is a morphological one, the primary etiological agent for the vast majority of cutaneous and mucosal papillomas is the Human Papillomavirus (HPV).7 Virology HPV is a small, non-enveloped, double-stranded, circular DNA virus 7 belonging to the Papillomaviridae family.9 It is a highly diverse viral family, with over 200 distinct types having been identified and sequenced.10 These viruses are epitheliotropic, meaning they specifically infect epithelial cells of the skin and mucous membranes. Epidemiology HPV infection is the most common sexually transmitted infection (STI) in the world.10 The prevalence is so high that nearly all sexually active individuals who are not vaccinated will acquire an HPV infection at some point in their lives.11 In the United States alone, it is estimated that more than 42 million Americans are currently infected, with approximately 13 to 14 million new infections occurring each year.10 Transmission The virus is spread primarily through intimate skin-to-skin contact.14 This includes vaginal, anal, or oral sex.13 A critical epidemiological feature of HPV is its ability to be transmitted by individuals who are asymptomatic and have no visible signs or symptoms of infection.13 Symptoms can also develop years after the initial infection, making it difficult to pinpoint the time of acquisition.13 While sexual contact is the predominant route for anogenital types, other routes exist. Vertical transmission from an infected mother to her infant during childbirth is a documented, albeit less common, route, which is the primary cause of juvenile-onset laryngeal papillomatosis.3 Natural History The vast majority (approximately 90%) of new HPV infections are clinically silent and are cleared spontaneously by a robust immune response, typically within two years of acquisition.9 These transient infections cause no long-term health problems. The clinical diseases associated with HPV—both benign papillomas and malignant cancers—are a consequence of the small percentage of infections that are not cleared by the immune system and establish a persistent infection.9

C. The Oncogenic Divide: HPV Subtype Classification

The more than 40 HPV types that preferentially infect the anogenital mucosa are categorized based on their epidemiologic association with cancer.10 This "oncogenic divide" is the most important concept in HPV-related pathology, as it directly dictates clinical risk and management. Low-Risk HPV (LR-HPV)

• Subtypes: This group primarily includes HPV types 6 and 11.3
• Clinical Lesions: LR-HPV types are associated with the classic, benign morphological papillomas.12 They are responsible for over 90% of all anogenital warts (Condylomata Acuminata) 12 and the vast majority of cases of Recurrent Respiratory Papillomatosis (RRP).12
• Malignant Potential: These types are considered non-oncogenic and rarely, if ever, cause cancer.16

High-Risk HPV (HR-HPV)

• Subtypes: This group includes approximately 12 types, most notably HPV types 16 and 18.9 Together, HPV 16 and 18 are responsible for approximately 70% of all cervical cancers and a majority of other HPV-related malignancies.9 Other high-risk types include 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.9
• Clinical Lesions: This is a critical distinction. HR-HPV infections are typically subclinical and do not cause the visible, exophytic papillomas or warts.1 Instead, a persistent infection with an HR-HPV type can lead to the development of flat, high-grade dysplastic lesions, which are true precancerous precursors.14
• Malignant Potential: These types are bona fide human carcinogens.12 They are the etiological agent for nearly all cervical cancers 9 and a significant majority of cancers of the anus, vagina, vulva, penis, and oropharynx (back of the throat, including the base of the tongue and tonsils).9

A paradox thus exists at the heart of HPV pathology. The virus family (Papillomaviridae) is named for the benign, wart-like growths it can produce. However, the most clinically significant and dangerous members of this family, the high-risk types 16 and 18, have evolved in a way that their infections are subclinical, non-papillomatous, and persistent, leading directly to the cellular changes that become high-grade dysplasia and, ultimately, invasive carcinoma.11 This biological bifurcation dictates two entirely different pathways of clinical management: one for the visible, benign (but sometimes morbid) papillomas, and another for the invisible, high-risk precancerous lesions.

D. Clarifying the Terminology: Papilloma, Condyloma, and Dysplasia

The evolution of a biological understanding of HPV has necessitated an evolution in the pathological terminology used to describe its lesions, moving away from a confusing mix of terms.24

• Papilloma / Condyloma: These terms are often used interchangeably, particularly in the anogenital tract (where condyloma acuminatum is the preferred term). They refer to the benign, exophytic, wart-like lesion 1 caused by LR-HPV types.22
• Dysplasia: This is a general, older pathological term meaning "disordered growth".24 It was historically graded as mild, moderate, or severe.
• Intraepithelial Neoplasia: In the 1970s, this term was introduced to create a site-specific classification:
• CIN (Cervical Intraepithelial Neoplasia)
• VAIN (Vaginal Intraepithelial Neoplasia)
• AIN (Anal Intraepithelial Neoplasia)
• These were graded 1 (mild dysplasia), 2 (moderate dysplasia), and 3 (severe dysplasia/carcinoma in situ).22

The Bethesda System and Lower Anogenital Squamous Terminology (LAST) The modern standard, the Bethesda System, unifies this terminology based on the HPV biology and the clinical behavior of the lesions.24 This system has been widely adopted because it provides superior clinical-pathological correlation.

• Low-Grade Squamous Intraepithelial Lesion (LSIL): This category encompasses what was formerly known as CIN 1 (mild dysplasia) and condyloma (papilloma).22 This unification is biologically sound, as both lesions represent a transient, productive HPV infection (usually with LR-HPV, or a transient HR-HPV infection).22 LSILs have a high rate of spontaneous regression and are not considered true precancer.26
• High-Grade Squamous Intraepithelial Lesion (HSIL): This category encompasses CIN 2 (moderate dysplasia) and CIN 3 (severe dysplasia/carcinoma in situ).22 This is a true precancerous lesion, caused by a persistent, transforming HR-HPV infection. HSIL has a high risk of progression to invasive cancer if left untreated.

This terminological shift from a three-tiered "dysplasia" system to a two-tiered "LSIL/HSIL" system is not merely semantic. It reflects a fundamental paradigm shift from simple morphological description to a biologically-driven classification that directly informs risk stratification and clinical management.24 LSIL is generally managed with surveillance, whereas HSIL requires excisional treatment.22

Table 1: Classification of Human Papillomavirus (HPV) Subtypes and Associated Clinical Lesions

Risk Category Common Subtypes Clinical Manifestations Malignant Potential Low-Risk (LR-HPV) 6, 11

• Anogenital Warts (Condylomata Acuminata) (>90% of cases)

• Recurrent Respiratory Papillomatosis (RRP)

• Oral Squamous Papillomas

• Conjunctival Papillomas

• Low-Grade Squamous Intraepithelial Lesions (LSIL)

Rarely Cause Cancer 16 Low-Risk (LR-HPV) 1, 2, 4, 7, 10, 22, 28, 63

• Common Warts (Verruca Vulgaris)

• Plantar Warts (Verruca Plantaris)

• Flat Warts (Verruca Plana)

None (Cutaneous types) 9 High-Risk (HR-HPV) 16, 18 (Cause ~70% of HPV cancers)

• High-Grade Squamous Intraepithelial Lesions (HSIL)

• Cervical, Vaginal, Vulvar, Anal, and Penile Cancers

• Oropharyngeal Cancers (back of throat)

High (Carcinogenic) 9 High-Risk (HR-HPV) 31, 33, 35, 39, 45, 51, 52, 56, 58, 59

• High-Grade Squamous Intraepithelial Lesions (HSIL)

• Cervical, Vaginal, Vulvar, Anal, and Penile Cancers

• Oropharyngeal Cancers

High (Carcinogenic) 9 3

II. Clinical Manifestations: A System-by-System Analysis of Papilloma Subtypes

The term "papilloma" is polyphyletic, describing a shared morphology that arises from different etiologies in diverse organ systems. The following analysis details the major clinical papilloma subtypes, differentiating between those that are HPV-driven and those that are not.

A. Cutaneous and Mucosal Squamous Papillomas

Cutaneous Papillomas (Warts) These are the most common benign epidermal growths, caused by cutaneous-specific HPV types.6

• Common Warts (Verruca Vulgaris): Caused by HPV types 2, 7, and 22.9 They appear as rough, raised, hyperkeratinized bumps, most frequently on the hands and fingers.23
• Plantar Warts (Verruca Plantaris): Caused by HPV types 1, 2, 4, and 63.9 These are hard, grainy growths on the heels or balls of the feet, which may cause discomfort or pain when walking.23
• Flat Warts (Verruca Plana): Caused by HPV types 3, 10, and 28.9 These are flat-topped, slightly raised lesions that can appear anywhere, often in clusters.23

Oral Squamous Papillomas These are common, benign lesions of the oral cavity.

• Location: They can arise from any squamous surface in the mouth, but are most common on the tongue, lips, inside of the cheek (buccal mucosa), and palate.1
• Etiology: The vast majority are caused by LR-HPV types 6 and 11.3
• Presentation: They typically present as painless, solitary, soft growths.3 They may be pedunculated (on a stalk) or sessile (broad-based).1 The classic appearance is "cauliflower-like," and the color ranges from pink to white depending on the degree of surface keratinization.1
• Prognosis: The prognosis is excellent. Oral squamous papillomas are benign, do not generally mutate to cancer, and do not spread.3 Recurrence after simple excision is rare.5
• Differential Diagnosis: They must be distinguished from other oral lesions, such as verruca vulgaris, verruciform xanthoma, and inflammatory papillary hyperplasia. Their presence may also be associated with certain rare inherited conditions, such as Cowden syndrome.5

B. Anogenital Papillomas (Condylomata Acuminata / Genital Warts)

• Location: These papillomas develop on the squamous epithelium of the anogenital tract 1, including the cervix, vagina, vulva, penis, scrotum, and perianal skin.6
• Etiology: Over 90% of cases are caused by LR-HPV types 6 and 11.9
• Presentation: The appearance is variable. They can be flat lesions, small cauliflower-like bumps, or tiny, stem-like projections.14 While often asymptomatic 14, they can cause itching, tenderness, or discomfort.23

C. Laryngeal and Recurrent Respiratory Papillomatosis (RRP)

• Location: RRP is characterized by the development of wart-like papillomas within the respiratory tract.29 The larynx (voice box) is the most frequently affected site, particularly the vocal cords.1 The disease can, however, spread to the trachea, bronchi, and, in rare, aggressive cases, the lung parenchyma.29
• Etiology: RRP is caused almost exclusively by LR-HPV types 6 and 11.12
• Clinical Course: The defining feature of this disease is its tendency for recurrence.20 RRP is a rare, chronic, and often unpredictable disease.20 It has a bimodal age distribution, affecting both children (Juvenile Onset RRP, or JORRP) and adults (Adult Onset RRP, or AORRP).21 JORRP is typically diagnosed before age 5 30 and, in some cases, may spontaneously remit during puberty.31
• Symptoms: Symptoms are directly related to the mass effect of the papillomas on the vocal cords and airway. The cardinal symptom is a change in voice, most commonly hoarseness.20 Other vocal changes include a raspy, breathy, or weak voice.20 As the papillomas grow, they can cause airway obstruction, leading to stridor (a high-pitched breathing sound), shortness of breath (dyspnea), chronic cough, and difficulty swallowing.20
• Prognosis: The papillomas themselves are benign in the vast majority of cases.21 The significant morbidity of RRP stems from its chronic, recurrent nature, which often necessitates multiple, frequent surgical procedures to maintain a patent airway and preserve voice.29 Malignant transformation to squamous cell carcinoma is a rare complication (less than 1% of cases) but has been documented.21

D. Papillary Lesions of the Breast (Intraductal Papilloma)

Intraductal papilloma represents a subtype that is defined by its papillary morphology, not an HPV etiology. These lesions are distinct from the viral papillomas, arising from different pathogenetic pathways and carrying different clinical implications. The risk factors for intraductal papilloma are hormonal, including contraceptive use, hormone replacement therapy, and lifetime estrogen exposure, as well as family history.33

• Definition: An intraductal papilloma is a benign, wart-like tumor that grows within a milk duct of the breast.34 Histologically, it maintains the classic papilloma structure: a fibrovascular core made of gland tissue, fibrous tissue, and blood vessels, covered by epithelial cells.35
• Classification and Presentation: Breast papillomas are classified based on their number and location, which strongly correlates with their clinical presentation and risk profile.
• Solitary (Central) Papilloma: This is the most common form, consisting of a single tumor located in a large milk duct near the nipple.34
• Symptoms: This type is the most common cause of clear or bloody nipple discharge, particularly when it is unilateral (originating from a single breast).34 It may also be felt as a small, palpable lump behind or adjacent to the nipple.34 It is typically not painful.36
• Cancer Risk: A single, solitary papilloma that does not contain atypical cells does not increase a person's lifetime risk of breast cancer.34 Its risk is comparable to other proliferative breast diseases without atypia.40
• Multiple (Peripheral) Papillomas / Papillomatosis: This condition involves multiple, smaller papillomas that develop in the smaller terminal ducts, farther away from the nipple.34
• Symptoms: These lesions are less likely to cause nipple discharge due to their location and small size.34 They are often asymptomatic and found incidentally on imaging 37, though they can present as a palpable mass if large or numerous.36
• Cancer Risk: Having multiple papillomas is associated with a slight increase in the lifetime risk of developing breast cancer.34

The Critical Distinction: Papilloma with Atypia The most important pathological determination for an intraductal papilloma is the presence or absence of "atypia." A papilloma can be overgrown by a secondary, monoclonal proliferation of cells that resemble Atypical Ductal Hyperplasia (ADH) or Ductal Carcinoma In Situ (DCIS).33 This entity, "papilloma with atypia," is classified as a high-risk precursor lesion.33 Its clinical significance lies in its frequent association with, or "upstaging" to, a more serious diagnosis upon full excision. A core needle biopsy (CNB) is a sampling tool and may only capture the atypical papilloma while missing an adjacent area of DCIS or even invasive carcinoma.43 The reported "upstaging" rate—the likelihood of finding malignancy at excision when only atypical papilloma is seen on CNB—is high, with some studies reporting it as high as 67%.44 For this reason, a CNB diagnosis of intraductal papilloma with atypia is a clear indication for mandatory surgical excision to obtain a definitive diagnosis and ensure adequate treatment.45

E. Sinonasal Inverted Papilloma (SNIP)

SNIP is another non-HPV-driven papilloma (though HPV has been implicated as a possible cofactor 46) that is defined by its unique morphology and aggressive clinical behavior. It is the most common of the three types of sinonasal papilloma (inverted, exophytic, and oncocytic).48

• Pathophysiology: Unlike an exophytic papilloma, the "inverted" papilloma is named for its characteristic growth pattern: the epithelium inverts and grows inward into the underlying connective tissue stroma.47
• Clinical Features: The "Benign but Aggressive" Triad: SNIP is a notorious entity in otolaryngology, known for a triad of features that dictates its aggressive management.

1. Symptoms: Patients typically present with unilateral symptoms that mimic chronic rhinosinusitis: persistent nasal congestion or obstruction, nasal drainage, postnasal drip, headaches, and a decreased sense of smell.46 2. Local Aggressiveness: Although histologically benign, SNIP is locally aggressive.46 Its inverted growth pattern allows it to remodel and destroy adjacent bone—a key diagnostic sign on CT scans.52 If left untreated, it can invade adjacent critical structures, including the orbit (eye) and the intracranial space (brain).47 3. High Recurrence Rate: SNIPs have a remarkably high tendency to recur after surgical removal, especially if the excision is incomplete.46 Reported recurrence rates vary widely in the literature, from 15-34% 46 to as high as 78%.49 Recurrence is strongly linked to failure to completely resect the tumor's "root" or mucosal attachment.55 Risk factors for recurrence include smoking and a history of prior surgery (implying residual disease).46

• Malignant Transformation: This is the most dangerous characteristic of SNIP. It carries a significant potential for malignant transformation into Squamous Cell Carcinoma (SCC). This rate is consistently reported to be in the range of 5% to 15%.47 This malignancy can be "synchronous" (present at the time of initial diagnosis) or "metachronous" (developing later, often in a recurrent lesion).53

The combination of these three features—local aggression, high recurrence, and malignant potential—means that SNIP is not managed like a simple benign polyp. Its clinical behavior demands treatment akin to a low-grade malignancy, with the primary goal being complete and total surgical eradication to achieve three-dimensional control.48 This requires meticulous preoperative planning with advanced imaging and aggressive, wide-field surgical techniques 55, followed by long-term surveillance to detect recurrence at its earliest, asymptomatic stage.47

F. Urothelial Papillomas of the Urinary Tract

Similar to breast papillomas, papillary lesions of the urinary tract (bladder, ureters, renal pelvis) are defined by their morphology, not an HPV etiology. The pathogenesis of these lesions is driven by chemical carcinogenesis.59 The single most important etiological factor is tobacco smoking, which is the leading cause of all bladder cancers and is responsible for approximately 50% of cases.8 Carcinogens from smoke are filtered by the kidneys, collect in the urine, and damage the urothelial lining.60 Other risk factors include workplace exposures to aromatic amines (used in the dye industry), arsenic in drinking water, and chronic bladder inflammation or infections.59 Histological Classification (WHO/ISUP) Papillary urothelial neoplasms are classified on a well-defined histopathological spectrum, as defined by the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP).63 1. Urothelial Papilloma: A rare, truly benign lesion. Histologically, it has an orderly arrangement of cells and a cell thickness resembling normal urothelium, but arranged in a delicate papillary formation.66 2. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP): This is a "borderline tumor".66 It is defined by a thicker epithelium (more cell layers) than a simple papilloma, with minimal to no architectural or nuclear atypia.66 3. Low-Grade Papillary Urothelial Carcinoma (LG-UrCa): This lesion shows greater, albeit still "low-grade," architectural disorder and nuclear atypia. 4. High-Grade Papillary Urothelial Carcinoma (HG-UrCa): This lesion is overtly malignant in appearance, with significant cellular atypia and architectural disarray.63 The PUNLMP Conundrum The PUNLMP category was created to identify a group of papillary lesions with such a low risk of recurrence or progression that they could be considered noncancerous.67 However, clinical data has complicated this distinction. Multiple studies have shown that the prognosis for PUNLMP, specifically its rates of recurrence and (rare) progression, is "more or less comparable" to that of G1/LG-UrCa.67 Both PUNLMP and LG-UrCa are characterized by a high rate of recurrence within the bladder, but a very low rate of progression to more dangerous, muscle-invasive disease.68 Because their clinical behavior and prognosis are so similar, the European Association of Urology (EAU) guidelines group PUNLMP and solitary, low-risk TaG1/LG tumors together for follow-up and management protocols.67

G. Choroid Plexus Papilloma (CPP)

This is a rare, non-HPV-related intracranial tumor, representing another instance of a morphological papilloma with a unique etiology and clinical presentation.

• Definition: A CPP is a rare, benign brain tumor 73 that arises from the epithelial cells of the choroid plexus, the structure within the brain's ventricles that produces cerebrospinal fluid (CSF).74
• Location: They have a predilection for different locations based on age, tending to be supratentorial (in the cerebral hemispheres) in children and infratentorial (in the posterior fossa) in adults.75
• Symptoms: The primary pathophysiology of CPP is the overproduction of CSF.74 This leads to a condition called communicating hydrocephalus ("water on the brain"), which increases intracranial pressure.75 Patients, often young children, present with symptoms of this pressure: headache, nausea, vomiting, or altered sensorium.75
• WHO Grading: These tumors are graded according to the WHO classification of CNS tumors.77
• Grade I: Choroid Plexus Papilloma (CPP): Benign, slow-growing, and does not spread.73
• Grade II: Atypical Plexus Papilloma (APP): Also slow-growing but has a higher risk of recurrence after resection.73
• Grade III: Choroid Plexus Carcinoma (CPC): The malignant, aggressive counterpart. It is more likely to spread.73
• Prognosis: The prognosis for a Grade I CPP is excellent. Gross total surgical resection is curative.75 Adjuvant radiation or chemotherapy is typically not required for these benign lesions.75

Table 2: Comparative Summary of Major Papilloma Subtypes

Subtype Primary Location(s) Primary Etiology Key Clinical Symptom(s) Recurrence Risk Malignant Potential Squamous Papilloma Oral Cavity, Skin, Genitals HPV (Low-Risk 6, 11) 3 Painless, "cauliflower-like" wart 3 Low (if excised) 5 Extremely Low / None 3 Recurrent Respiratory Papillomatosis (RRP) Larynx (Vocal Cords) HPV (Low-Risk 6, 11) 12 Hoarseness, stridor, airway obstruction 20 Very High (Chronic) 20 Rare (<1%) 21 Intraductal Papilloma Breast (Milk Ducts) Hormonal / Genetic 33 Unilateral bloody/clear nipple discharge 34 Low (if excised) None (if solitary, no atypia).34 High-risk if multiple 37 or with atypia 33 Sinonasal Inverted Papilloma (SNIP) Nasal Cavity, Paranasal Sinuses Unknown (HPV-associated?) 46 Unilateral nasal obstruction (mimics sinusitis) 47 High (15-78%) 46 High (5-15%) Transformation to SCC 49 Urothelial Papilloma / PUNLMP Urinary Bladder Tobacco Smoke / Chemical Carcinogens 60 Painless hematuria (blood in urine) 61 High (chronic) 67 Low (progression risk is low, but it is a "borderline" lesion) 67 Choroid Plexus Papilloma (CPP) Brain (Ventricles) Unknown / Congenital Headache, vomiting (from hydrocephalus) 75 Low (if resected) None (Grade I is benign; cured by surgery) 75

III. Diagnostic Evaluation and Clinical Workup

A. Clinical Presentation and Physical Examination (Summary)

The diagnostic process begins with the patient's chief complaint, which varies significantly by papilloma type and location.

• Cutaneous/Anogenital: Presents as a visible, palpable lesion, often described as a "wart" or "cauliflower-like" growth.14
• Intraductal (Breast): The classic presentation is spontaneous, unilateral nipple discharge, which may be clear or, more concerningly, bloody. A small, periareolar lump may also be palpable.35
• RRP (Laryngeal): The hallmark is persistent hoarseness or a weak, breathy voice. In advanced cases, this progresses to audible stridor or shortness of breath.20
• SNIP (Sinonasal): Presentation is often indolent, mimicking chronic rhinosinusitis with unilateral nasal obstruction, persistent drainage, and facial pressure.47
• Urothelial (Bladder): The cardinal sign is painless hematuria (blood in the urine).61
• Choroid Plexus (Brain): Presentation reflects increased intracranial pressure from hydrocephalus, including headache, nausea, vomiting, and (in infants) an enlarging head circumference.75

B. Imaging Modalities

Imaging is essential for characterizing lesions in non-visible locations, assessing their extent, and planning surgical intervention.

• Breast (Intraductal Papilloma):
• Mammogram: May be normal or show non-specific findings like a mass, nodule, or calcifications.37
• Ultrasound: Often the preferred initial imaging modality, especially for a palpable lump or when a mammogram is normal. It is highly effective at confirming an intraductal lesion.37
• Breast MRI: May be used if a patient has classic symptoms (i.e., nipple discharge) but both mammogram and ultrasound are inconclusive.37
• Ductogram (Galactogram): A specialized X-ray where contrast dye is injected into the discharging duct. This can precisely outline the duct and pinpoint the "filling defect" of the papilloma, but it is less commonly used now.35
• Sinonasal (SNIP):
• A dual-modality approach is the standard of care.
• Computed Tomography (CT): This is the essential modality for evaluating bone. It can demonstrate pathognomonic signs of SNIP's aggressive nature, such as bone destruction, erosion, or focal hyperostosis (bony thickening).46
• Magnetic Resonance Imaging (MRI): This is superior for soft tissue detail. It is used to assess the tumor's extent and its invasion into adjacent soft tissues, the orbit, or the brain (intracranial extension).51 The combination of CT and MRI provides the complete map necessary for safe and effective surgical planning.58
• Brain (Choroid Plexus Papilloma):
• Cranial imaging is required for any patient with symptoms of hydrocephalus. MRI is the preferred modality for evaluating the tumor, its location, and the degree of associated hydrocephalus.75

C. Histopathological Diagnosis (Biopsy)

A tissue biopsy for histopathological analysis is the gold standard for the definitive diagnosis of any papilloma and for distinguishing it from a malignant mimic.3

• Breast: The standard is an image-guided (usually ultrasound-guided) Core Needle Biopsy (CNB).37 The pathologist's report on the CNB (e.g., "benign papilloma" vs. "papilloma with atypia") is the critical data point that dictates subsequent management.45
• Sinonasal / Laryngeal: Diagnosis is made via an endoscopic biopsy performed during nasal endoscopy or laryngoscopy.51
• Urothelial: Diagnosis is made during Cystoscopy, a procedure where a small camera is inserted into the bladder. Visible lesions are then biopsied or completely resected via a procedure called Transurethral Resection (TUR).68
• Oral / Cutaneous: A simple excisional biopsy or shave biopsy is typically both diagnostic and curative.3

D. Virological and Molecular Testing (Anogenital/Cervical)

The diagnostic framework for anogenital lesions is unique. It is not designed to find and diagnose visible, benign papillomas (warts), which are clinically obvious. Instead, it is a comprehensive cancer prevention and screening system designed to detect and risk-stratify the subclinical, flat, high-risk HPV infections that lead to cancer.11

• Cervical Pap Test (Cytology): A screening test that uses a microscope to look for "abnormal cells" (dysplasia/SIL) on the cervix.11 It is a morphological test, not a viral test.
• HPV Test (DNA/mRNA): A molecular test that detects the presence of the virus itself. Screening tests are specifically designed to look for the DNA of the high-risk HPV types.81
• Co-testing: Performing both a Pap test and an HPV test at the same time.81
• Primary HPV Testing: Using the HPV test as the primary, stand-alone screening tool.81
• Self-collection: An emerging option allowing a person to collect a vaginal sample at home for HPV testing.81
• E6/E7 mRNA Test: This is a more specific type of HPV test. Instead of just detecting viral DNA (which could be from a transient, harmless infection), this test detects the mRNA for the E6 and E7 oncoproteins.81 The expression of E6 and E7 is the mechanism by which HR-HPV subverts the cell cycle and causes cancer. Therefore, a positive E6/E7 test indicates a high-risk, active, transforming infection that is far more likely to progress to cancer.81
• Colposcopy / High-Resolution Anoscopy (HRA):
• These are follow-up diagnostic procedures, not screening tests. They are performed after a patient has an abnormal Pap test or a positive HR-HPV test.78
• A magnifying instrument (colposcope or anoscope) is used to visually inspect the cervix or anus. Acetic acid is applied to highlight abnormal areas, allowing the physician to perform directed biopsies of the most suspicious lesions.78

IV. Management, Treatment, and Prognosis

A. Principles of Excision and Ablation (for Benign HPV-driven Lesions)

For benign HPV-driven papillomas, such as cutaneous warts, oral papillomas, and anogenital warts, the goal of treatment is the physical removal or destruction of the lesion.

• Surgical Excision: Simple surgical removal with a scalpel.1
• Ablative/Destructive Therapies:
• Cryotherapy: This is a very common, minimally invasive outpatient procedure that uses liquid nitrogen to freeze and destroy the abnormal tissue.1 It is effective and results in minimal scarring.84
• Electrosurgery / Electrocautery: Uses an electrical current to "burn" off and destroy the lesion.1
• Laser Ablation: Uses an intense light beam (e.g., $CO_2$ laser) to vaporize and destroy the tissue.1
• Topical Medical Therapies: These are applied directly to the lesion.
• Keratolytic Agents: Topical salicylic acid compounds break down the keratin in the wart.3
• Antimitotic Agents: Podofilox (Condylox) is a prescription cream that kills the dividing wart tissue.83
• Chemical Cautery: Trichloroacetic acid (TCA) is a chemical applied by a provider to burn off warts.11
• Immune Modulators: Imiquimod (Zyclara) is a prescription cream that does not attack the wart directly, but rather stimulates the body's local immune system to recognize and fight the HPV virus.4

B. Specialized Management by Subtype

Intraductal Papilloma (Breast) Management is entirely dictated by the histopathological findings from the core needle biopsy.

• Papilloma with Atypia (ADH/DCIS): A diagnosis of atypia on CNB mandates surgical excision.42 This is not to treat the atypical papilloma, but to perform a diagnostic excision to rule out a more significant, "upstaged" lesion like DCIS or invasive carcinoma that was missed by the needle.44
• Benign Papilloma (No Atypia): This is a more controversial area.1 Surgical excision is not considered mandatory for asymptomatic, small, benign papillomas where the imaging findings are fully concordant with the biopsy result.45 However, excision is still recommended for patients who are symptomatic (palpable mass, nipple discharge) or have larger lesions (e.g., >1 cm).45

Sinonasal Inverted Papilloma (SNIP) Given its aggressive nature and malignant potential, the treatment for SNIP is aggressive surgery with the goal of complete, en bloc resection.51

• The modern "gold standard" is Endoscopic Endonasal Surgery.54 This minimally invasive approach has been shown to have recurrence rates comparable to, or even better than, older, more morbid external approaches (e.g., facial incisions).88
• The surgical keynote is the complete removal of the tumor and its mucosal attachment ("root"), which is the source of recurrence.55 This often requires an Endoscopic Medial Maxillectomy (EMM), which involves removing the medial wall of the maxillary sinus to gain wide access, or a prelacrimal approach.54
• Intra-operative frozen sections may be used to confirm that the margins of the resection are clear of the tumor.87

Recurrent Respiratory Papillomatosis (RRP) There is no "cure" for RRP.21 Management is palliative and is focused on two goals: 1) maintaining a safe and patent airway, and 2) preserving voice quality.21

• Surgical Debulking: This is the mainstay of treatment.29 This involves the surgical removal of the papillomas, often with microdebriders or lasers, to clear the airway. For many patients, these procedures must be repeated frequently, sometimes multiple times per year, for life.29
• Adjuvant Therapies: For patients with very aggressive disease (approximately 20% of patients), adjuvant medical therapies may be used to reduce tumor growth and lengthen the interval between surgeries.29
• Intralesional Cidofovir: An antiviral injected into the lesions.29
• Bevacizumab (Avastin): An anti-VEGF agent (which blocks blood vessel formation) that can be given systemically or injected. Systemic bevacizumab appears to be the most effective adjuvant treatment currently available.91
• HPV Vaccine (Gardasil): In a novel application, studies have shown that the HPV vaccine, when given to an already-infected patient, can act as an adjuvant therapeutic agent, stimulating the immune system to slow tumor growth and reduce the need for surgery.29

Urothelial Papilloma / PUNLMP

• The initial management for any new papillary bladder lesion is Transurethral Resection of Bladder Tumor (TURBT), which removes the lesion for pathological analysis.72
• Given the high recurrence rate, patients are placed on a strict surveillance protocol. New, recurrent low-grade tumors can often be managed with simple outpatient cystoscopic fulguration (burning) rather than a full TURBT in an operating room.72

Choroid Plexus Papilloma (CPP)

• The definitive treatment is Gross Total Resection (Surgery).75
• For benign Grade I CPP, this surgery is curative.75 Adjuvant therapy is not indicated.75

C. Prognosis and Long-Term Surveillance

The long-term prognosis of a "papilloma" is entirely dependent on its type and location. This prognosis is governed by a critical dichotomy: the risk of recurrence versus the risk of progression to cancer. The "High Recurrence, Low Progression" Pathway This group includes diseases that are chronic and morbid but rarely life-threatening.

• RRP: Defined by its relentless recurrence, requiring repeated surgeries.29 The risk of malignant progression is very low (<1%).21
• Urothelial PUNLMP / LG-UrCa: These lesions have a very high rate of recurrence (up to 67%).68 However, the risk of progression to life-threatening muscle-invasive bladder cancer is very low (e.g., 0.5% mortality).72
• Surveillance: Because of the high recurrence risk, lifelong surveillance is mandatory for urothelial lesions.68 A typical "low-risk" (PUNLMP or LG-UrCa) protocol from the EAU involves cystoscopy at 3 months, 12 months, and then annually for 5 years.79 Other common protocols involve cystoscopy every 3-4 months for 2 years, then semiannually, and then annually.68

The "High Progression / Malignant Potential" Pathway This group includes lesions that are feared not for their recurrence, but for their high risk of being or becoming an invasive cancer.

• SNIP: Feared for its 5-15% rate of transformation to Squamous Cell Carcinoma.49
• Breast Papilloma with Atypia: Feared for its high "upstaging" rate, where the true diagnosis upon excision is DCIS or invasive carcinoma.33
• Surveillance:
• SNIP: Long-term follow-up with endoscopic evaluation is mandatory to detect asymptomatic recurrence or metachronous malignancy.47 This follow-up is typically continued for at least 3-5 years post-surgery.47
• Breast (w/ Atypia): Patients are not just "cured" by excision. The diagnosis of atypia places them in a high-risk category, and they are typically referred to a high-risk breast clinic for enhanced lifetime screening (e.g., alternating mammograms and MRIs) and consideration of chemoprevention.45
• Anogenital (HR-HPV): Persistent high-risk HPV infection requires routine, lifelong screening via Pap/HPV testing to intercept the 5-20 year progression to cancer.11

Table 3: Histological Classification and Prognosis of Papillary Urothelial Neoplasms (WHO/ISUP)

Neoplasm Category Key Histological Features Recurrence Rate Risk of Progression to Muscle-Invasive Disease Urothelial Papilloma Papillary fronds with fibrovascular cores. Lined by urothelium that is histologically normal and of normal thickness. 63 Low Very Low / None PUNLMP (Papillary Urothelial Neoplasm of Low Malignant Potential) Thicker urothelium (>7 cell layers). Minimal architectural disorder. Minimal to no nuclear atypia. 63 High 67 Very Low 67 Low-Grade (LG) Papillary Urothelial Carcinoma Thicker urothelium. Conspicuous architectural disorder. Mild, but overt, nuclear atypia (variation in size/shape, irregular chromatin). 63 High 68 Low 70 High-Grade (HG) Papillary Urothelial Carcinoma Significant architectural disorder (e.g., fused papillae). Overt, severe nuclear atypia (pleomorphism, prominent nucleoli, high mitotic rate). 63 High High 63

V. Prevention and Public Health

A "papilloma" is not one disease, and therefore its prevention is not one strategy. The correct preventative measures must be stratified by the specific etiology of the papilloma type.

A. Primary Prevention: HPV Vaccination

For the most common papillomas—cutaneous, oral, laryngeal (RRP), and anogenital—the etiological agent is HPV. The best and most effective preventative strategy is HPV vaccination.95

• Vaccine: The 9-valent (Gardasil 9) vaccine, used in the United States, is a powerful preventative tool.12
• Protection: It is designed to protect against the 9 most clinically relevant HPV types:
• 7 High-Risk Types (16, 18, 31, 33, 45, 52, 58): These cause the vast majority of HPV-related cancers.17
• 2 Low-Risk Types (6, 11): These cause >90% of all genital warts and RRP.12
• Efficacy: The vaccine is highly effective, preventing over 90% of cancers caused by HPV.99 Real-world data from a cohort of 1.7 million Swedish women found that vaccination, particularly when given early, reduced the diagnosis of cervical cancer by nearly 90%.100
• CDC/ACIP Guidelines:
• Routine Age: Vaccination is routinely recommended for all preteens at age 11–12 years.95 It can be started as early as age 9.95
• Dosing:
• 2-Dose Schedule: Individuals who start the series before their 15th birthday need only 2 doses, given 6–12 months apart.95
• 3-Dose Schedule: Individuals who start the series at age 15–26, or who are immunocompromised, require a 3-dose schedule (at 0, 1–2, and 6 months).80
• Catch-up: Vaccination is recommended for everyone through age 26 who was not adequately vaccinated when younger.80
• Adults 27–45: Vaccination is not routinely recommended for all adults in this age group. The decision should be based on "shared clinical decision-making" between the patient and provider.80 The vaccine is most effective before any sexual activity (and thus before exposure) 100; its benefit decreases in older adults who are more likely to have already been exposed.96

B. Secondary Prevention: Screening (Anogenital)

For high-risk, cancer-causing HPV infections (which are subclinical), secondary prevention through screening is the cornerstone of public health.

• Cervical Screening: Regular Pap tests and/or HPV testing (as detailed in Section III.D) are used to detect high-grade dysplasia (HSIL).11
• Goal: The progression from persistent HR-HPV infection to precancer (HSIL) and then to invasive cancer can take 5 to 20 years.17 This long latent period provides a wide window of opportunity for screening to detect and treat the precancerous lesion, thereby preventing invasive cancer from ever developing.11

C. Risk Reduction Strategies

For HPV-Related Lesions:

• Abstinence: Abstaining from sexual activity is the only 100% reliable method to prevent genital HPV infection.80
• Condoms: Condoms, when used consistently and correctly, can lower the chances of HPV transmission and HPV-related diseases.11 However, they do not eliminate the risk.96 HPV is transmitted by skin-to-skin contact, and condoms do not cover all infected areas of the genital skin (e.g., scrotum, vulva).80
• Limiting Partners: Reducing the number of sexual partners can reduce the risk of acquiring HPV.80

For Urothelial Lesions:

• Smoking Cessation: For the non-HPV-driven papillomas of the urinary tract, the single most important preventative measure is smoking cessation.60 Former smokers have a significantly higher risk of recurrence and grade progression than non-smokers.104

VI. Conclusion

The term "papilloma" is a foundational concept in pathology, but it is a polyphyletic one. It does not describe a single entity but is rather a broad morphological classification, defined by an exophytic growth of epithelium over a fibrovascular core 2, that applies to at least five mechanistically distinct disease categories with profoundly different prognoses and management strategies. 1. HPV-Driven Benign Lesions: This group includes cutaneous, oral, and anogenital papillomas (warts), as well as Recurrent Respiratory Papillomatosis (RRP). These are overwhelmingly caused by Low-Risk HPV types 6 and 11.3 Their management involves local ablation or excision.1 Their prognosis for malignancy is excellent (near zero), though RRP is defined by its high morbidity from chronic recurrence.29 2. HPV-Driven Malignant Precursors: Paradoxically, the most dangerous High-Risk HPV types 16 and 18 do not typically cause papillomas.11 Instead, they cause flat, subclinical, persistent infections that lead to high-grade squamous intraepithelial lesions (HSIL)—the true precursors to anogenital and oropharyngeal cancers.17 3. Non-HPV, "Benign but Aggressive" Lesions: This category is uniquely occupied by the Sinonasal Inverted Papilloma (SNIP). It is a histologically benign lesion that is managed as a low-grade malignancy due to its triad of local aggression, high recurrence rate, and significant (5-15%) potential for malignant transformation to squamous cell carcinoma.49 4. Non-HPV, Risk-Stratified Lesions: This group includes Intraductal Papillomas (Breast) and Urothelial Papillomas (Bladder). These are non-HPV-driven lesions.33 Their entire clinical management hinges on pathological risk stratification: for the breast, the presence of atypia 45, and for the bladder, the histopathological grade (e.g., PUNLMP vs. LG-UrCa).67 5. Non-HPV, Truly Benign Lesions: This category includes the Choroid Plexus Papilloma, a rare intracranial tumor that causes hydrocephalus but is considered cured by complete surgical resection.75 A clear understanding of this etiological and behavioral diversity is essential for diagnosis, management, and prevention. Treatment can range from simple topical cream for a skin wart to aggressive neurosurgery for a CPP or radical endoscopic resection for a SNIP. Prevention, likewise, must be etiology-specific, from HPV vaccination as a public health imperative for one set of diseases 95 to smoking cessation as the critical intervention for another.61 Nguồn trích dẫn 1. Papillomas: A Multisystem Overview of HPV-Associated and HPV-Independent Lesions – StatPearls – NCBI, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560737/ 2. Papilloma – MeSH – NCBI – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/sites/entrez?Db=mesh&Cmd=DetailsSearch&Term=%22Papilloma%22%5BMeSH+Terms%5D 3. Squamous cell papilloma – Wikipedia, truy cập vào tháng 11 12, 2025, https://en.wikipedia.org/wiki/Squamous_cell_papilloma 4. Squamous Papilloma – Exodontia.info, truy cập vào tháng 11 12, 2025, https://exodontia.info/squamous-papilloma/ 5. Squamous Papilloma on the Hard Palate: A Rare Clinical Entity – PMC – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10246509/ 6. Squamous cell papilloma – DermNet, truy cập vào tháng 11 12, 2025, https://dermnetnz.org/topics/squamous-cell-papilloma 7. Human Papillomavirus – StatPearls – NCBI Bookshelf, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK448132/ 8. Papilloma: Causes, Symptoms, Pictures, Treatment, and More – Healthline, truy cập vào tháng 11 12, 2025, https://www.healthline.com/health/papilloma 9. Human papillomavirus infection – Wikipedia, truy cập vào tháng 11 12, 2025, https://en.wikipedia.org/wiki/Human_papillomavirus_infection 10. Chapter 5: Human Papillomavirus | Manual for the Surveillance of Vaccine-Preventable Diseases | CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-5-human-papillomavirus.html 11. HPV (Human Papillomavirus): Causes, Symptoms & Treatment – Cleveland Clinic, truy cập vào tháng 11 12, 2025, https://my.clevelandclinic.org/health/diseases/11901-hpv-human-papilloma-virus 12. Chapter 11: Human Papillomavirus | Pink Book – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-11-human-papillomavirus.html 13. About Genital HPV Infection | STI – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/sti/about/about-genital-hpv-infection.html 14. Types of Human Papillomavirus | NYU Langone Health, truy cập vào tháng 11 12, 2025, https://nyulangone.org/conditions/human-papillomavirus/types 15. About HPV – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/hpv/about/index.html 16. Definition of low-risk HPV – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/low-risk-hpv 17. HPV and Cancer – NCI, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer 18. Cervical Cancer Causes, Risk Factors, and Prevention – NCI, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/types/cervical/causes-risk-prevention 19. Types of HPV | American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/risk-prevention/hpv/types-of-hpv.html 20. Laryngeal Papillomatosis | Atrium Health Wake Forest Baptist, truy cập vào tháng 11 12, 2025, https://www.wakehealth.edu/condition/l/laryngeal-papillomatosis 21. Recurrent Respiratory Papillomatosis: A Rare Chronic Disease, Difficult to Treat, with Potential to Lung Cancer Transformation: Apropos of Two Cases and a Brief Literature Review – PMC – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3081647/ 22. Human Papillomavirus and Cervical Cancer – PMC, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC145302/ 23. HPV infection – Symptoms & causes – Mayo Clinic, truy cập vào tháng 11 12, 2025, https://www.mayoclinic.org/diseases-conditions/hpv-infection/symptoms-causes/syc-20351596 24. Lower Anogenital Standardized Terminology—The LAST Step? – Incyte Diagnostics, truy cập vào tháng 11 12, 2025, https://www.incytediagnostics.com/about/news-and-publications/lower-anogenital-standardized-terminology-the-last-step/ 25. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology – Allen Press, truy cập vào tháng 11 12, 2025, https://meridian.allenpress.com/aplm/article/136/10/1266/133088/The-Lower-Anogenital-Squamous-Terminology 26. Definition of cervical dysplasia – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cervical-dysplasia 27. HPV Signs and Symptoms | American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/risk-prevention/hpv/hpv-signs-and-symptoms.html 28. Definition of oral papilloma – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oral-papilloma 29. Recurrent Respiratory Papillomatosis: Symptoms & Treatment – Cleveland Clinic, truy cập vào tháng 11 12, 2025, https://my.clevelandclinic.org/health/diseases/23101-recurrent-respiratory-papillomatosis 30. Laryngeal Papillomatosis | Stanford Health Care, truy cập vào tháng 11 12, 2025, https://stanfordhealthcare.org/medical-conditions/ear-nose-and-throat/vocal-cord-disorders/types/laryngeal-papillomatosis.html 31. Pediatric laryngeal papillomas – Children's Health ENT, truy cập vào tháng 11 12, 2025, https://www.childrens.com/specialties-services/conditions/laryngeal-papillomas 32. About RRP – RRPF – The Recurrent Respiratory Papillomatosis Foundation, truy cập vào tháng 11 12, 2025, https://rrpf.org/about-rrp/ 33. Intraductal Papilloma – StatPearls – NCBI Bookshelf – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK519539/ 34. Definition of intraductal papilloma – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/intraductal-papilloma 35. Intraductal Papillomas of the Breast | Benign Conditions | American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/intraductal-papillomas.html 36. Intraductal Papilloma: What It Is, Breast Symptoms & Treatment – City of Hope, truy cập vào tháng 11 12, 2025, https://www.cityofhope.org/clinical-program/breast-cancer/facts/intraductal-papilloma 37. Intraductal Papilloma: Symptoms, Diagnosis, Treatment & Surgery – Cleveland Clinic, truy cập vào tháng 11 12, 2025, https://my.clevelandclinic.org/health/diseases/intraductal-papilloma 38. truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/intraductal-papillomas.html#:~:text=They%20are%20a%20common%20cause,breast%20farther%20from%20the%20nipple. 39. Intraductal papilloma: MedlinePlus Medical Encyclopedia, truy cập vào tháng 11 12, 2025, https://medlineplus.gov/ency/article/001238.htm 40. Breast Intraductal Papillomas Without Atypia in Radiologic- Pathologic Concordant Core-Needle Biopsies: Rate of Upgrade to Carcinoma at Excision, truy cập vào tháng 11 12, 2025, https://www.surgonc.org/wp-content/uploads/2019/03/Breast-Fellows-Webinar-Feb-2017-Article-3.pdf 41. Breast Intraductal Papillomas without Atypia in Radiologic-Pathologic Concordant Core Needle Biopsies: Predictors of Upgrade to Carcinoma at Excision – PMC, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5014573/ 42. Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/8912836/ 43. Papillary Lesions of the Breast: A Practical Approach to Diagnosis – Allen Press, truy cập vào tháng 11 12, 2025, https://meridian.allenpress.com/aplm/article/140/10/1052/65387/Papillary-Lesions-of-the-Breast-A-Practical 44. Are We Overtreating Papillomas Diagnosed on Core Needle Biopsy? – PMC, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3980447/ 45. Intraductal papillomas of the breast – Calvillo – Annals of Breast Surgery, truy cập vào tháng 11 12, 2025, https://abs.amegroups.org/article/view/7004/html 46. Clinical characteristics and recurrence predictors of sinonasal inverted papilloma: a retrospective cohort study – Frontiers, truy cập vào tháng 11 12, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1537905/full 47. Inverted Papillomas | Mount Sinai – New York, truy cập vào tháng 11 12, 2025, https://www.mountsinai.org/care/ent/services/nasal-sinus-allergy/conditions/inverted-papilloma 48. table of contents previous next A true papilloma of the mucosa of the nose and paranasal sinuses, the inverted papilloma is the, truy cập vào tháng 11 12, 2025, https://medicine.osu.edu/-/media/files/medicine/departments/otolaryngology/atlas-of-head-and-neck-pathology/s/sinonasalpapillomas2.pdf?la=en&hash=EAA6EE5138A923E2E49F45D8A889316276DE9956 49. Sinonasal inverted papilloma: rate of recurrence and malignant transformation in 44 operated patients – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9422717/ 50. Histology and histogenesis of two different types of inverted urothelial papillomas – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/6821821/ 51. Inverted Papilloma – Symptoms and Causes – Penn Medicine, truy cập vào tháng 11 12, 2025, https://www.pennmedicine.org/conditions/inverted-papilloma 52. Differences in Imaging and Histology Between Sinonasal Inverted Papilloma with and Without Squamous Cell Carcinoma – MDPI, truy cập vào tháng 11 12, 2025, https://www.mdpi.com/2075-4418/15/13/1645 53. Sinonasal Inverted Papillomas: Recurrence, and Synchronous and Metachronous Malignancy – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/17319993/ 54. Surgery of Inverted Papilloma of the Maxillary Sinus via Translacrimal Approach—Long-Term Outcome and Literature Review – MDPI, truy cập vào tháng 11 12, 2025, https://www.mdpi.com/2077-0383/8/11/1873 55. Surgical management of inverted papillomas of the paranasal sinuses, truy cập vào tháng 11 12, 2025, https://otorhinolaryngologypl.com/seo/article/146345/en 56. Malignant transformation of sinonasal inverted papilloma: A retrospective analysis of 32 cases – Spandidos Publications, truy cập vào tháng 11 12, 2025, https://www.spandidos-publications.com/10.3892/ol.2014.2539 57. Squamous Cell Carcinoma Arising from Sinonasal Inverted Papilloma, truy cập vào tháng 11 12, 2025, https://www.ajnr.org/content/41/7/1156 58. Risk Factors for Recurrence after Surgical Resection of Sinonasal Inverted Papilloma – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11511273/ 59. Inverted Urothelial Papilloma – StatPearls – NCBI Bookshelf – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537218/ 60. Urothelial carcinoma: 8 insights about this common bladder cancer, truy cập vào tháng 11 12, 2025, https://www.mdanderson.org/cancerwise/urothelial-carcinoma–8-insights-about-this-common-bladder-cancer.h00-159697545.html 61. Papillary Urothelial Carcinoma: Treatment, Prognosis, and More – Healthline, truy cập vào tháng 11 12, 2025, https://www.healthline.com/health/papillary-urothelial-carcinoma 62. Bladder Cancer Risk Factors | How Do You Get Bladder Cancer? – American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/types/bladder-cancer/causes-risks-prevention/risk-factors.html 63. Papillary Urothelial Neoplasms: Clinical, Histologic, and Prognostic Features – NCBI – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK585967/ 64. Papilloma, PUNLMP, Low-Grade Uroth. CA – Webpathology, truy cập vào tháng 11 12, 2025, https://www.webpathology.com/images/genitourinary/urinary-bladder/papilloma-punlmp-low-grade-uroth-ca 65. Outline, truy cập vào tháng 11 12, 2025, https://auau.auanet.org/sites/default/files/Urothelial%20Carcinoma.pdf 66. Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis – PMC – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4503134/ 67. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category – Cloudfront.net, truy cập vào tháng 11 12, 2025, https://d56bochluxqnz.cloudfront.net/documents/guideline-publications/non-muscle-invasive-bladder-cancer/Papillary-urothelial-neoplasm-of-low-malignant-potential…-Urol-Oncol-2020-38-440.pdf 68. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT – PMC, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5604438/ 69. Papillary Urothelial Neoplasia with Low Malignant Potential (PUNLMP) in a 9-year-old Child: A Case Report and – Pediatric Sciences Journal, truy cập vào tháng 11 12, 2025, https://cupsj.journals.ekb.eg/article_387126_43cb7eda609b8235fa56f5e1ee8af7fd.pdf 70. Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Post–World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center – Allen Press, truy cập vào tháng 11 12, 2025, https://meridian.allenpress.com/aplm/article/134/8/1160/461120/Low-Grade-Papillary-Urothelial-Carcinoma-of-the 71. Poster: Recurrence and progression rates of urothelial papillomas of the urinary bladder – F1000Research, truy cập vào tháng 11 12, 2025, https://f1000research.com/posters/5-2389 72. Management of Low Grade Papillary Bladder Tumors – Journal of Urology, truy cập vào tháng 11 12, 2025, https://www.auajournals.org/doi/pdf/10.1016/j.juro.2007.05.148 73. Choroid Plexus Brain Tumor | Boston Children's Hospital, truy cập vào tháng 11 12, 2025, https://www.childrenshospital.org/conditions/choroid-plexus-brain-tumor 74. Choroid Plexus Tumors, truy cập vào tháng 11 12, 2025, https://braintumorcenter.ucsf.edu/condition/choroid-plexus-tumors 75. Choroid Plexus Papilloma – StatPearls – NCBI Bookshelf – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539749/ 76. Choroid Plexus Papilloma – Cedars-Sinai, truy cập vào tháng 11 12, 2025, https://www.cedars-sinai.org/health-library/diseases-and-conditions/c/what-is-choroid-plexus-papilloma.html 77. Choroid Plexus – American Brain Tumor Association | Learn More, truy cập vào tháng 11 12, 2025, https://www.abta.org/tumor_types/choroid-plexus/ 78. Diagnosing Human Papillomavirus – NYU Langone Health, truy cập vào tháng 11 12, 2025, https://nyulangone.org/conditions/human-papillomavirus/diagnosis 79. FOLLOW-UP OF PATIENTS WITH NMIBC – Uroweb, truy cập vào tháng 11 12, 2025, https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/followup-of-patients-with-nmibc 80. Human Papillomavirus (HPV) Infection – STI Treatment Guidelines – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/std/treatment-guidelines/hpv.htm 81. HPV Testing | Diagnosing HPV – American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/risk-prevention/hpv/hpv-and-hpv-testing.html 82. HPV test – Mayo Clinic, truy cập vào tháng 11 12, 2025, https://www.mayoclinic.org/tests-procedures/hpv-test/about/pac-20394355 83. HPV infection – Diagnosis & treatment – Mayo Clinic, truy cập vào tháng 11 12, 2025, https://www.mayoclinic.org/diseases-conditions/hpv-infection/diagnosis-treatment/drc-20351602 84. Cryosurgery | Dermatology Procedure, truy cập vào tháng 11 12, 2025, https://www.advanceddermnco.com/procedures/cryosurgery 85. Cryotherapy: Uses, Procedure, Risks & Benefits – Cleveland Clinic, truy cập vào tháng 11 12, 2025, https://my.clevelandclinic.org/health/treatments/21099-cryotherapy 86. Cutaneous Cryosurgery for Common Skin Conditions – AAFP, truy cập vào tháng 11 12, 2025, https://www.aafp.org/pubs/afp/issues/2020/0401/p399.html 87. Management of Sinonasal Inverted Papillomas: Endoscopic Medial Maxillectomy, truy cập vào tháng 11 12, 2025, https://www.e-mjm.org/2008/v63n1/Sinonasal_Inverted_Papillomas.pdf 88. Endoscopic removal of sinonasal inverted papilloma including endoscopic medial maxillectomy – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/12792324/ 89. Endoscopic medial maxillectomy with preservation of inferior turbinate in maxillary sinus inverted papilloma – Pan Arab Journal of Rhinology, truy cập vào tháng 11 12, 2025, https://pajr.researchcommons.org/cgi/viewcontent.cgi?article=1080&context=journal 90. Laryngeal Papillomas – StatPearls – NCBI Bookshelf – NIH, truy cập vào tháng 11 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK562327/ 91. Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults | The Journal of Laryngology & Otology, truy cập vào tháng 11 12, 2025, https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology/article/adjuvant-treatments-for-recurrent-respiratory-papillomatosis-a-descriptive-review-and-proposed-management-guideline-in-adults/6D1E0092686DAF42F206DC103E2E19B0 92. Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/39429135/ 93. Current and future management of recurrent respiratory papillomatosis – PMC – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5824106/ 94. Management and treatment of sinonasal inverted papilloma – PMC – NIH, truy cập vào tháng 11 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4755686/ 95. HPV Vaccination – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/hpv/vaccines/index.html 96. How to Protect Against HPV | American Cancer Society, truy cập vào tháng 11 12, 2025, https://www.cancer.org/cancer/risk-prevention/hpv/hpv-prevention.html 97. Protect Yourself Against HPV | NIH News in Health, truy cập vào tháng 11 12, 2025, https://newsinhealth.nih.gov/2013/10/protect-yourself-against-hpv 98. HPV Vaccination | CDC Recommendations, truy cập vào tháng 11 12, 2025, https://www.merckvaccines.com/gardasil9/cdc-recommendations/ 99. HPV (Human Papillomavirus) Vaccine – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/vaccines/hcp/current-vis/downloads/hpv.pdf 100. Preventive cervical cancer vaccine for women and girls: Side effects, protection provided and who should not take it, truy cập vào tháng 11 12, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/preventive-cervical-cancer-vaccine-for-women-and-girls-side-effects-protection-provided-and-who-should-not-take-it/articleshow/125244933.cms 101. HPV Vaccine Recommendations – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/hpv/hcp/vaccination-considerations/index.html 102. HPV Vaccination Recommendations – CDC, truy cập vào tháng 11 12, 2025, https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html 103. Protecting yourself against HPV – Mayo Clinic Health System, truy cập vào tháng 11 12, 2025, https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/protecting-yourself-against-hpv 104. Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome – PubMed, truy cập vào tháng 11 12, 2025, https://pubmed.ncbi.nlm.nih.gov/36055007/